Diagnostic Management of Benign and Malignant Pheochromocytoma

Abstract

As rare and thus often overlooked hormone-secreting tumors, pheochromocytomas pose a particular diagnostic challenge. Difficulties involve biochemical confirmation, localizing, and detection of malignancy. Measurement of free plasma metanephrines, genetic testing and specific imaging procedures - such as MIBG and octreotide scintigraphy or fluorodopamine PET - represent a considerable progress, and the management of benign pheochromocytomas has become very effective. However, a comparable improvement in the prognosis of malignant chromaffin cell tumors, which occur in approximately 10-15% of all cases, has not yet been achieved. Here, telomerase catalytic subunit (hTERT) activity and heat shock protein 90 expression could serve both as molecular markers allowing an earlier diagnosis of malignancy and as therapeutic targets. Familial syndromes should be considered both in benign and malignant pheochromocytoma, and should be tested for prior to surgery in selected patient groups.

pheochromocytoma - metanephrines - genetics - diagnostic imaging

References

• 1 Bender BU, Altehofer C, Januszewicz A, Gartner R, Schmidt H, Hoffmann MM, Heidemann PH, Neumann HP. Functioning thoracic paraganglioma: association with Von Hippel-Lindau syndrome.  J Clin Endocrinol Metab. 1997;  82 3356-3360
• 2 Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O, Henley D, Herman P, Murday V, Niccoli-Sire P, Pasieka JL, Rohmer V, Tucker K, Jeunemaitre X, Marsh DJ, Plouin PF, Robinson BG. Clinical presentation and penetrance of Pheochromocytoma/Paraganglioma syndromes.  J Clin Endocrinol Metab. 2006;  91 827-836
• 3 Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, Mawrin C, Hoang-Vu C, Roessner A, Lehnert H. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma.  J Clin Endocrinol Metab. 2003;  88 4280-4286
• 4 Bornstein SR, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma: increasing importance for clinical decision making.  Ann N Y Acad Sci. 2006;  1073 94-103
• 5 Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects.  Endocr Rev. 2003;  24 539-553
• 6 Bravo EL, Tarazi RC, Fouad FM, Vidt DG, Gifford Jr RW. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma.  N Engl J Med. 1981;  305 623-626
• 7 Bravo EL, Tarazi RC, Gifford RW, Stewart BH. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications.  N Engl J Med. 1979;  301 682-686
• 8 Senanayake PS, Denker J, Bravo EL, Graham RM. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma.  J Clin Invest. 1995;  96 2503-2509
• 9 Edström Elder E, Xu D, Hoog A, Enberg U, Hou M, Pisa P, Gruber A, Larsson C, Backdahl M. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.  Mod Pathol. 2003;  16 246-255
• 10 Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young Jr WF. Malignant pheochromocytoma: current status and initiatives for future progress.  Endocr Relat Cancer. 2004;  11 423-436
• 11 Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results.  J Clin Endocrinol Metab. 2003;  88 2656-2666
• 12 Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A, Lenders JW. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors.  J Clin Endocrinol Metab. 1998;  83 2175-2185
• 13 Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM, Brouwers FM, Pacak K. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines.  Clin Chem. 2005;  51 735-744
• 14 Eisenhofer G, Lenders JW, Linehan WM, Walther MM, Goldstein DS, Keiser HR. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2.  N Engl J Med. 1999;  340 1872-1879
• 15 Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors.  Am J Pathol. 2002;  161 1235-1246
• 16 Francis IR, Korobkin M. Pheochromocytoma.  Radiol Clin North Am. 1996;  34 1101-1112
• 17 Fujita A, Hyodoh H, Kawamura Y, Kanegae K, Furuse M, Kanazawa K. Use of fusion images of I-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma.  Clin Nucl Med. 2000;  25 440-442
• 18 Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau VK, Corvol P, Plouin PF, Jeunemaitre X. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.  Cancer Res. 2003;  63 5615-5621
• 19 Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP. The genetic basis of pheochromocytoma.  Front Horm Res. 2004;  31 45-60
• 20 Goldstein RE, O'Neill Jr JA, Holcomb III GW, Morgan III WM, Neblett III WW, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott Jr HW. Clinical experience over 48 years with pheochromocytoma.  Ann Surg. 1999;  229 755-764
• 21 Grossman A, Pacak K, Sawka A, Lenders JW, Harlander D, Peaston RT, Reznek R, Sisson J, Eisenhofer G. Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus?.  Ann N Y Acad Sci. 2006;  1073 332-347
• 22 Grossman E, Goldstein DS, Hoffman A, Keiser HR. Glucagon and clonidine testing in the diagnosis of pheochromocytoma.  Hypertension. 1991;  17 733-741
• 23 Ilias I, Pacak K. Anatomical and functional imaging of metastatic pheochromocytoma.  Ann N Y Acad Sci. 2004;  1018 495-504
• 24 Januszewicz A, Neumann HP, Lon I, Szmigielski C, Symonides B, Kabat M, Apel TW, Wocial B, Lapinski M, Januszewicz W. Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients.  J Hypertens. 2000;  18 1019-1023
• 25 Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.  J Clin Endocrinol Metab. 2001;  86 895-902
• 26 Kaltsas GA, Papadogias D, Grossman AB. The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas).  Front Horm Res. 2004;  31 61-75
• 27 Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, Hensen J, Lehnert H. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma.  Clin Endocrinol (Oxf). 1997;  46 39-44
• 28 Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma.  Lancet. 2005;  366 665-675
• 29 Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, Kloppenborg PW, Thien T, Eisenhofer G. Plasma metanephrines in the diagnosis of pheochromocytoma.  Ann Intern Med. 1995;  123 101-109
• 30 Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best?.  JAMA. 2002;  287 1427-1434
• 31 Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H, Dralle H. Codon-specific development of peochromocytoma in multiple endocrine neoplasia type 2.  J Clin Endocrinol Metab. 2005;  90 3999-4003
• 32 Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, Norton JA, Walther MM, Keiser HR, Neumann RD. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI.  J Nucl Med. 1993;  34 173-179
• 33 Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C. Germ-line mutations in nonsyndromic pheochromocytoma.  N Engl J Med. 2002;  346 1459-1466
• 34 Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA, Hoegerle S, Boedeker CC, Opocher G, Schipper J, Januszewicz A, Eng C. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.  JAMA. 2004;  292 943-951
• 35 Neumann HP, Reincke M, Bender BU, Elsner R, Janetschek G. Preserved adrenocortical function after laparoscopic bilateral adrenal sparing surgery for hereditary pheochromocytoma.  J Clin Endocrinol Metab. 1999;  84 2608-2610
• 36 NIH . NIH state-of-the-science statement on management of the clinically inapparent adrenal mass (“incidentaloma”).  NIH Consens State Sci Statements. 2002;  19 1-25
• 37 Pacak K, Eisenhofer G, Carrasquillo JA, Chen CC, Li ST, Goldstein DS. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma.  Hypertension. 2001a;  38 6-8
• 38 Pacak K, Eisenhofer G, Ilias I. Diagnostic imaging of pheochromocytoma.  Front Horm Res. 2004;  31 107-120
• 39 Pacak K, Goldstein DS, Doppman JL, Shulkin BL, Udelsman R, Eisenhofer G. A “pheo” lurks: novel approaches for locating occult pheochromocytoma.  J Clin Endocrinol Metab. 2001b;  86 3641-3646
• 40 Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma.  Ann Intern Med. 2001c;  20 315-329
• 41 Quint LE, Glazer GM, Francis IR, Shapiro B, Chenevert TL. Pheochromocytoma and paraganglioma: comparison of MR imaging with CT and I-131 MIBG scintigraphy.  Radiology. 1987;  165 89-93
• 42 Salmenkivi K, Haglund C, Ristimaki A, Arola J, Heikkila P. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.  J Clin Endocrinol Metab. 2001;  86 5615-5619
• 43 Salmenkivi K, Heikkila P, Liu J, Haglund C, Arola J. VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome.  APMIS. 2003;  111 458-464
• 44 Sawka AM, Gafni A, Thabane L, Young Jr WF. The economic implications of three biochemical screening algorithms for pheochromocytoma.  J Clin Endocrinol Metab. 2004a;  89 2859-2866
• 45 Sawka AM, Prebtani AP, Thabane L, Gafni A, Levine M, Young Jr WF. A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma.  BMC Endocr Disord. 2004b;  4 2
• 46 Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET.  Radiology. 1999;  212 35-41
• 47 van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, van de Meiracker AH, Boomsma F, Stijnen T, Krenning EP, Bosman FT, Kwekkeboom DJ. ¹²³I]metaiodobenzylguanidine and [¹¹¹In]octreotide uptake in benign and malignant pheochromocytomas.  J Clin Endocrinol Metab. 2001;  86 685-693
• 48 Yon L, Guillemot J, Montero-Hadjadje M, Grumolato L, Leprince J, Lefebvre H, Contesse V, Plouin PF, Vaudry H, Anouar Y. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors.  J Clin Endocrinol Metab. 2003;  88 2579-2585

Correspondence